| Generic/working name | Lenvatinib |
| Drug type | Small molecule |
| Drug class | Angiogenesis—VEGF |
| Route | Oral (po) |
| Schedule of administration | In this 3+3 dose-escalation study, patients received lenvatinib with capecitabine (850 mg/m2/BID daily) and radiation on days 1–5 each week (Monday–Friday) for a total of 5½–6 weeks (28 fractions with a total intended dose of 5040 cGy). The doses of lenvatinib tested were 14 mg daily for cohort 1, 20 mg for cohort 2, and 24 mg for cohort 3. |
| Generic/working name | Capecitabine |
| Drug type | Chemotherapy |
| Route | Oral (po) |
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.